Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Study Overview
=================
Brief Summary
-----------------
To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China

Detailed Description
-----------------
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease all over the world (1). In early 2020, a new definition of MAFLD has been proposed and is becoming increasingly widely accepted. The new diagnostic criteria are based on the histology or imaging of liver biopsies, or even blood biomarker tests indicative of the presence of fatty liver while satisfying any one of the following three conditions: overweight/obesity, type 2 diabetes, or metabolic dysfunction (2). The information on the prevalence of MAFLD is scarce. This study is designed to conduct MAFLD screening in adults with health check-ups at multiple health examination centers across China. The primary objective is to investigate the prevalence of MAFLD among adults in China.

Official Title
-----------------
Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Conditions
-----------------
Fatty Liver Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Fibrotouch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged between 18 and 75, both sex; Able to sign informed consent. Exclusion Criteria: Pregnant women and those who are implanted with pacemakers, stents or any other metal devices.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Single Group Assignment<br>Adults with health check-ups at multiple health examination centers across China | Diagnostic Test: Fibrotouch<br>* Fibrotouch will be performed showing the stiffness and fat content of liver<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To investigate the prevalence of MAFLD among adults at multiple health examination centers across China. | MAFLD means metabolic dysfunction-associated fatty liver disease | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the proportion of overweight or obese patients with MAFLD (BMI≥23 kg/m²). | MAFLD means metabolic dysfunction-associated fatty liver disease; BMI means body mass index | through study completion, an average of 1 year | 
| To assess the prevalence of metabolic dysfunction among patients with MAFLD who are lean or normal in body weight (BMI < 23 kg/m²) | MAFLD means metabolic dysfunction-associated fatty liver disease; BMI means body mass index | through study completion, an average of 1 year | 
| To assess the prevalence of type 2 diabetes among patients with MAFLD. | MAFLD means metabolic dysfunction-associated fatty liver disease | through study completion, an average of 1 year | 
| To assess the prevalence of liver fibrosis and cirrhosis among patients with MAFLD. | MAFLD means metabolic dysfunction-associated fatty liver disease | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MAFLD